JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A2412 CP-724714

Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R

Summary: HER2 inhibitor,potent and selective

≥23.5 mg/mL
A5057 MGCD-265

Target: VEGFR|c-MET

Summary: Met/Flt/Flk/Ron/Tie-2 inhibitor

≥25.9 mg/mL
A1778 Vatalanib (PTK787) 2HCl

Target: VEGFR

Summary: Tyrosine kinase receptor inhibitor

≥21 mg/mL
A8683 NVP-BHG712

Target: Eph Receptors|VEGFR

Summary: EphB4 inhibitor,potent and selective

≥25.15 mg/mL
B2172 PP121

Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck

Summary: Dual inhibitor of tyrosine and phosphoinositide kinases
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL